Aclaris Therapeutics, Inc. (ACRS) News
Filter ACRS News Items
ACRS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ACRS News Highlights
- For ACRS, its 30 day story count is now at 2.
- Over the past 16 days, the trend for ACRS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ACRS are DRUG.
Latest ACRS News From Around the Web
Below are the latest news stories about ACLARIS THERAPEUTICS INC that investors may wish to consider to help them evaluate ACRS as an investment opportunity.
Aclaris Therapeutics (NASDAQ:ACRS) pulls back 7.4% this week, but still delivers shareholders massive 110% CAGR over 3 yearsAclaris Therapeutics, Inc. ( NASDAQ:ACRS ) shareholders have seen the share price descend 10% over the month. But over... |
Aclaris Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceWAYNE, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, CEO of Aclaris, will virtually present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, which will be available on-demand beginning on Monday, September 12, 2022 at 7:00 a.m. ET. Management will be available September |
Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia AreataWAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced a non-exclusive patent license agreement with Eli Lilly and Company (Lilly). Under the license agreement, Aclaris granted Lilly non-exclusive rights under certain patents and patent applications that Aclaris exclusively licenses from The Trustees of Columbia University in t |
H.C. Wainwright Sticks to Its Buy Rating for Aclaris Therapeutics (ACRS)In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aclaris Therapeutics (ACRS - Research Report), with a price target of $50.00. The company's shares closed last Friday at $18.00.Selvaraju covers the Healthcare sector, focusing on stocks such as Regulus, Aeterna Zentaris, and Oncternal Therapeutics. According to TipRanks, Selvaraju has an average return of -35.9% and a 19.40% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aclaris Therapeutics with a $35.33 average price target, implying a 96.28% upside from current levels. |
Health Check: How Prudently Does Aclaris Therapeutics (NASDAQ:ACRS) Use Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously... |
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Misses Revenue EstimatesAclaris (ACRS) delivered earnings and revenue surprises of 13.89% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? |
Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update•Appointed Douglas Manion, M.D., FRCP (C), as President and COO •Initiated Phase 2a Study Activities for Psoriatic Arthritis WAYNE, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2022 and provided a corporate update. “It has been a busy first half of the year as we continue in ou |
Aclaris Therapeutics Expands Leadership TeamAppoints Douglas Manion, M.D., FRCP (C), as President and COO WAYNE, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as President and Chief Operating Officer. Dr. Manion will be responsible for overseeing day-to-day operations, continuing to develop Aclaris’ infrastructure and |
Here's Why Aclaris Therapeutics (ACRS) is a Great Momentum Stock to BuyDoes Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out. |
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?Here is how Aclaris Therapeutics (ACRS) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year. |